Vericel Corp (NASDAQ:VCEL) was the recipient of unusually large options trading activity on Tuesday. Stock investors bought 1,948 call options on the company. This represents an increase of approximately 3,507% compared to the average volume of 54 call options.
NASDAQ VCEL opened at $16.65 on Wednesday. Vericel has a 52 week low of $3.30 and a 52 week high of $17.26. The company has a quick ratio of 7.48, a current ratio of 7.72 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $513.57 million, a price-to-earnings ratio of -33.30 and a beta of 3.36.
Vericel (NASDAQ:VCEL) last posted its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.09. The business had revenue of $22.50 million during the quarter, compared to analysts’ expectations of $18.14 million. Vericel had a negative net margin of 23.35% and a negative return on equity of 37.86%. Vericel’s revenue for the quarter was up 57.3% compared to the same quarter last year. As a group, equities analysts expect that Vericel will post -0.41 earnings per share for the current year.
In other news, insider Dominick Colangelo sold 75,000 shares of the company’s stock in a transaction dated Thursday, October 4th. The shares were sold at an average price of $15.02, for a total value of $1,126,500.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Gerard J. Michel sold 15,000 shares of the company’s stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $12.35, for a total transaction of $185,250.00. Following the completion of the sale, the chief financial officer now owns 165,960 shares in the company, valued at approximately $2,049,606. The disclosure for this sale can be found here. Insiders sold a total of 114,000 shares of company stock worth $1,609,770 in the last quarter. 4.70% of the stock is currently owned by company insiders.
Large investors have recently modified their holdings of the stock. Capital Fund Management S.A. purchased a new stake in shares of Vericel in the 2nd quarter valued at approximately $104,000. Quantitative Systematic Strategies LLC purchased a new stake in shares of Vericel in the 2nd quarter valued at approximately $108,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Vericel in the 2nd quarter valued at approximately $116,000. Commonwealth Equity Services LLC purchased a new stake in shares of Vericel in the 2nd quarter valued at approximately $123,000. Finally, Metropolitan Life Insurance Co. NY purchased a new stake in shares of Vericel in the 2nd quarter valued at approximately $128,000. Institutional investors and hedge funds own 76.57% of the company’s stock.
Several research firms recently weighed in on VCEL. Needham & Company LLC increased their price objective on shares of Vericel to $18.00 and gave the stock a “buy” rating in a research note on Tuesday. BTIG Research upped their target price on shares of Vericel from $17.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday. LADENBURG THALM/SH SH upgraded shares of Vericel from a “neutral” rating to a “buy” rating in a research report on Monday, July 16th. Finally, BidaskClub cut shares of Vericel from a “hold” rating to a “sell” rating in a research report on Tuesday, October 23rd. One analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $16.75.
TRADEMARK VIOLATION WARNING: This article was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/11/07/stock-traders-buy-high-volume-of-vericel-call-options-vcel.html.
Vericel Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure.
Featured Article: Closed-End Mutual Funds (CEFs)
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.